DEADLINE ALERT for HYLN, HIMS, UNCY, BIDU: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

Law Offices of Howard G. Smith has filed securities fraud class action lawsuits against four publicly-traded companies: Hyliion Holdings Corp., Hims & Hers Health Inc., Unicycive Therapeutics Inc., and Baidu Inc. The lawsuits allege that defendants made materially false and misleading statements and failed to disclose material adverse facts about their respective businesses. Investors have until specified deadlines in late October and November 2026 to file lead plaintiff motions.

10/01/2026, 4:00 PM • GlobeNewswire

Deadline Alert: Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

Unicycive Therapeutics faces a class action securities fraud lawsuit after the FDA issued a Complete Response Letter (CRL) on June 30, 2026, citing the same third-party manufacturing deficiencies as a previous rejection. The company's stock fell 39.1% following the announcement. The lawsuit alleges defendants made false statements and failed to disclose that the company had not properly audited its manufacturing vendor's compliance with FDA standards.

09/29/2026, 2:45 PM • GlobeNewswire

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY

Rosen Law Firm is soliciting investors for multiple securities class action lawsuits. The primary case involves Unicycive Therapeutics, which allegedly made false statements about its manufacturing vendor's FDA compliance and the regulatory approval timeline for its drug oxylanthanum carbonate. The firm is also handling class actions for FuelCell Energy and GoDaddy, with lead plaintiff deadlines approaching in November 2026.

09/28/2026, 7:16 PM • GlobeNewswire

UNCY Stockholders Have Rights – If You Lost Money Investing in Unicycive Therapeutics, Inc. Contact Robbins LLP for Information About Recovering Your Losses

A class action lawsuit was filed against Unicycive Therapeutics (UNCY) for allegedly failing to disclose that it had not inspected its third-party manufacturing vendor's facility before resubmitting a New Drug Application to the FDA. The company's stock dropped 39.1% on June 30, 2026, when the FDA issued a Complete Response Letter citing the same manufacturing deficiencies previously identified. Investors who purchased UNCY securities between December 29, 2025 and June 29, 2026 may be eligible to participate in the lawsuit.

09/25/2026, 2:57 PM • GlobeNewswire

ROSEN, NATIONAL TRIAL LAWYERS, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY

A securities class action lawsuit has been filed against Unicycive Therapeutics, Inc. for allegedly making materially false and misleading statements regarding FDA compliance at its third-party manufacturing vendor. The lawsuit claims the company failed to disclose that it had not inspected the vendor's facility or audited compliance with manufacturing practices, creating undisclosed risks of regulatory delays for its oxylanthanum carbonate drug. Investors who purchased securities between December 29, 2025 and June 29, 2026 may be entitled to compensation. The lead plaintiff deadline is November 2, 2026.

09/22/2026, 7:33 PM • GlobeNewswire

ROSEN, A LEADING NATIONAL FIRM, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY

Rosen Law Firm is seeking lead plaintiffs for a securities class action lawsuit against Unicycive Therapeutics, Inc. The lawsuit alleges that the company made materially false and misleading statements regarding its manufacturing vendor's FDA compliance and the regulatory approval timeline for its drug oxylanthanum carbonate. Investors who purchased UNCY securities between December 29, 2025 and June 29, 2026 may be eligible to join the class action with a November 2, 2026 deadline to serve as lead plaintiff.

09/18/2026, 12:58 PM • GlobeNewswire

Kirby McInerney LLP Alerts Investors Who Acquired Unicycive Therapeutics, Inc. UNCY Securities Between December 29, 2025 and June 29, 2026 of Pending Lawsuit

A securities class action lawsuit has been filed against Unicycive Therapeutics for allegedly making false statements about its manufacturing vendor's FDA compliance. The company failed to disclose that it had not inspected the third-party facility or audited its compliance with manufacturing practices. On June 30, 2026, the FDA issued a second Complete Response Letter citing the same manufacturing deficiencies, causing Unicycive's stock to plummet 39.1% to $4.69 per share. The lead plaintiff deadline is November 2, 2026.

09/17/2026, 10:00 AM • GlobeNewswire

ROSEN, HIGHLY RECOGNIZED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY

Rosen Law Firm has filed a class action lawsuit on behalf of Unicycive Therapeutics investors who purchased securities between December 29, 2025 and June 29, 2026. The lawsuit alleges that Unicycive made materially false and misleading statements regarding its third-party manufacturing vendor's FDA compliance and failed to disclose risks of regulatory delays for its oxylanthanum carbonate drug. Investors must move the court by November 2, 2026 to serve as lead plaintiff.

09/13/2026, 12:24 AM • GlobeNewswire

Bronstein, Gewirtz & Grossman LLC Urges Unicycive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Unicycive Therapeutics, Inc. alleging that the company made materially false and misleading statements regarding its third-party manufacturing vendor's FDA compliance. The complaint claims Unicycive failed to inspect the vendor's facility and lacked reasonable basis to believe deficiencies were remedied, creating undisclosed risks of regulatory delays for oxylanthanum carbonate approval. Investors who purchased securities between December 29, 2025 and June 29, 2026 may be eligible to join the case.

09/07/2026, 12:46 PM • GlobeNewswire

UNCY: Unicycive Therapeutics Investors with Losses Should Contact Block & Leviton About Securities Fraud Investigation

Block & Leviton is investigating Unicycive Therapeutics for potential securities law violations related to false or misleading statements about FDA review of its OLC New Drug Application. The company received a second Complete Response Letter on June 30, 2026, citing manufacturing deficiencies, which led to a stock price decline. Investors who have suffered losses are encouraged to contact the firm.

07/13/2026, 2:05 PM • GlobeNewswire

ALHC ALERT: Block & Leviton Investigating Alignment Healthcare, Inc. For Possible Securities Fraud; Investors Should Contact Block & Leviton to Learn More

Block & Leviton is investigating Alignment Healthcare, Inc. (ALHC) for potential securities law violations following allegations that a former executive filed a whistleblower lawsuit claiming the company manipulated finances to boost stock price and executive compensation. The stock fell approximately 16.72% following the report. The firm is also investigating Jefferies Financial Group and Unicycive Therapeutics for similar violations.

07/08/2026, 5:47 PM • GlobeNewswire

Johnson Fistel Investigates Unicycive Therapeutics, Inc. (NASDAQ: UNCY) on Behalf of Investors

Johnson Fistel is investigating Unicycive Therapeutics after the FDA issued a second Complete Response Letter on June 30, 2026, citing the same third-party manufacturing deficiencies from a prior CRL. The FDA had not yet inspected the manufacturing vendor at the time of the resubmission. The announcement led to a decline in Unicycive's stock price, prompting investigation into potential false or misleading statements.

06/30/2026, 12:51 PM • GlobeNewswire

Important Notice to Long-Term Shareholders of ASP Isotopes Inc. (NASDAQ: ASPI); Integer Holdings Corp. (NYSE: ITGR): Soleno Therapeutics, Inc. (NASDAQ: SLNO); and Unicycive Therapeutics, Inc. (NASDAQ: UNCY): Grabar Law Office is Investigating Claims on Your Behalf

Grabar Law Office is investigating securities fraud claims against four companies: ASP Isotopes for allegedly making false statements about uranium enrichment technology; Integer Holdings for overstating competitive position and concealing sales deterioration; Soleno Therapeutics for misrepresenting safety profile of drug candidate DCCR/VYKAT XR; and Unicycive Therapeutics for overstating FDA manufacturing compliance readiness. Shareholders who purchased shares during specified periods may be eligible to seek corporate reforms and compensation.

03/18/2026, 9:17 AM • GlobeNewswire

Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Unicycive Therapeutics, Inc. (NASDAQ: UNCY); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office is Investigating Claims on Your Behalf

Grabar Law Office is investigating potential securities fraud and fiduciary duty breaches for several publicly traded companies, alleging misleading statements and incomplete disclosures that potentially harmed shareholders.

12/02/2025, 12:39 PM • GlobeNewswire

Bragar Eagel & Squire is Investigating Certain Officers and Directors of Quantum, Unicycive, Fly-E, and Lantheus on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Law firm investigating potential securities misconduct for four companies, alleging false statements, misleading financial reporting, and concealment of material facts that impacted stock prices.

11/13/2025, 5:40 PM • GlobeNewswire